This page is currently under revision. Read this statement from the Panel's for the most recent information on the use of tixagevimab plus cilgavimab (Evusheld) as PrEP of COVID-19.

Table A. SARS-CoV-2 Variants Currently or Recently Circulating in the United States and Their Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies

Last Updated: December 28, 2022

For information on SARS-CoV-2 variants that were previously circulating in the United States, see the Guidelines Archive.

Table A. SARS-CoV-2 Variants Currently or Recently Circulating in the United States and Their Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies
WHO Label and Pango Lineage	BEB		TIX Plus CIL^a		BAM Plus ETE		CAS Plus IMD		SOT
WHO Label and Pango Lineage	In Vitro Susceptibility^b	Anticipated Clinical Activity	In Vitro Susceptibility^b	Anticipated Clinical Activity	In Vitro Susceptibility^b	Anticipated Clinical Activity	In Vitro Susceptibility^b	Anticipated Clinical Activity	In Vitro Susceptibility^b	Anticipated Clinical Activity
Omicron BA.5	No change	Active	Moderate reduction	Active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active
Omicron BA.4.6/BF.7	No change	Active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active
Omicron BQ.1	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active
Omicron BQ.1.1	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active
Omicron XBB	Marked reduction^1,2	Unlikely to be active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active	Marked reduction	Unlikely to be active
^a Other variants are expected to be resistant to TIX plus CIL (e.g., BA.5.2.6, BF.11, BA.2.75.2). However, these variants currently represent a small proportion of the circulating variants in the United States. ^b This information is based on the fold reduction in susceptibility reported in the FDA EUAs.^3-7 Key: BAM = bamlanivimab; BEB = bebtelovimab; CAS = casirivimab; CIL = cilgavimab; ETE = etesevimab; EUA = Emergency Use Authorization; FDA = Food and Drug Administration; IMD = imdevimab; SOT = sotrovimab; TIX = tixagevimab; WHO = World Health Organization

References

Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2022. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36476720.
Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2022;Published online ahead of print. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36580913.
Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization (EUA) of bamlanivimab and etesevimab. 2022. Available at: https://www.fda.gov/media/145802/download.
Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization (EUA) of REGEN-COV (casirivimab and imdevimab). 2021. Available at: https://www.fda.gov/media/145611/download.
Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization (EUA) of sotrovimab. 2022. Available at: https://www.fda.gov/media/149534/download.
Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab). 2022. Available at: https://www.fda.gov/media/154701/download.
Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for bebtelovimab. 2022. Available at: https://www.fda.gov/media/156152/download.